在疑似脓毒症患者评估中,白介素-6联合医生判断可提高感染识别能力
这项前瞻性观察研究在两家城市学术型急诊科纳入2016年6月至2017年12月收治的器官功能障碍成人患者,最终306例纳入分析,154例(50.3%)为感染性病因。医生判断识别感染的AUC为0.78(95%CI 0.74-0.82),优于最佳生物标志物模型白介素-6单用(AUC 0.71,95%CI 0.66-0.76)。医生判断联合白介素-6后AUC提高至0.84(95%CI 0.79-0.87),AUC改善0.06(95%CI 0.03-0.08)。作者认为,在急诊器官功能障碍患者中,血浆白介素-6可能改善联合医生判断时的感染识别能力。
要点
- 纳入标准为收治的成人患者,满足以下之一:两条全身炎症反应综合征标准加器官功能障碍、收缩压<90 mmHg、或乳酸≥4.0 mmol/L。
- 医生判断识别感染的AUC为0.78(95%CI 0.74-0.82),优于白介素-6单用的AUC 0.71(95%CI 0.66-0.76)。
- 医生判断联合白介素-6后AUC为0.84(95%CI 0.79-0.87),AUC改善0.06(95%CI 0.03-0.08)。
- 最终分析306例中154例(50.3%)为感染性病因,医生正确区分感染与非感染病因239例(78.1%)。
适用人群与场景
- 两家城市学术型急诊科收治的成人患者,满足以下之一:两条全身炎症反应综合征标准加器官功能障碍、收缩压<90 mmHg、或乳酸≥4.0 mmol/L。
- 排除创伤、因颅内出血转院、或无可用血样的患者。
研究设计与关键结果
- 前瞻性观察研究,2016年6月至2017年12月在两家城市学术型急诊科进行,纳入421例,最终306例符合研究标准。
- 306例中154例(50.3%)为感染性病因,医生正确区分感染与非感染病因239例(78.1%)。
- 医生判断识别感染的AUC为0.78(95%CI 0.74-0.82),优于白介素-6单用(AUC 0.71,95%CI 0.66-0.76)。
- 医生判断联合白介素-6后AUC为0.84(95%CI 0.79-0.87),AUC改善0.06(95%CI 0.03-0.08)。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在急诊器官功能障碍患者中,血浆白介素-6可能改善联合医生判断时的感染识别能力。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Identifying infection is critical in early sepsis screening. This study assessed whether biomarkers of endothelial activation and/or inflammation could improve identification of infection among Emergency Department (ED) patients with organ dysfunction.
METHODS: We performed a prospective, observational study at two urban, academic EDs, between June 2016 and December 2017. We included admitted adults with 1) two systemic inflammatory response syndrome criteria and organ dysfunction, 2) systolic blood pressure < 90 mmHg, or 3) lactate ≥4.0 mmol/L. We excluded patients with trauma, transferred for intracranial hemorrhage, or without available blood samples. Treating ED physicians reported presence of infection (yes/no) at inpatient admission. Assays for angiopoietin-1, angiopoietin-2, soluble tumor necrosis factor receptor-1, interleukin-6, and interleukin-8 were performed using ED blood samples. The primary outcome was infection, adjudicated by paired physician review. Using logistic regression, we compared the performance of physician judgment, biomarkers, and physician judgment-biomarkers combination to predict infection. Area under the curve (AUC) and AUC 95% confidence intervals were estimated by bootstrap procedure.
RESULTS: Of 421 patients enrolled, 306 patients met final study criteria. Of these, 154(50.3%) patients had infectious etiologies. Physicians correctly discriminated infectious from non-infectious etiologies in 239 (78.1%). Physician judgment performed moderately when discriminating infection (AUC 0.78, 95% CI: 0.74-0.82) and outperformed the best biomarker model, interleukin-6 alone, (AUC 0.71, 0.66-0.76). Physician judgment improved when including interleukin-6 (AUC 0.84, 0.79-0.87), with modest AUC improvement: 0.06 (0.03-0.08).
CONCLUSIONS: In ED patients with organ dysfunction, plasma interleukin-6 may improve infection discrimination when added to physician judgment.
参考来源
- Henning DJ, Hall MK, Watsjold BK, et al. Interleukin-6 improves infection identification when added to physician judgment during evaluation of potentially septic patients. Am J Emerg Med. 2019. PMID: 31375355. doi:10.1016/j.ajem.2019.158361
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。